Please login to the form below

Not currently logged in
Email:
Password:

BMS lobbying spend reaches USD 2.8m

Bristol-Myers Squibb spent over USD 2.8m in H1 2007 to lobby the US Federal government over patent protection

US-headquartered pharmaceutical company Bristol-Myers Squibb (BMS) spent over USD 2.8m in H1 2007 to lobby the US Federal government over patent protection.

The company continues to lobby for patent protection for the pharmaceutical industry, free trade agreements and more funding for the FDA, according to a form posted online by the Senate's public records office on 10 October 2007.

In early September 2007, the House approved a patent reform bill intended to reduce patent litigation, improve patent quality, increase information available to patent examiners and establish a post-approval patent re-evaluation process.

While technology and financial services firms supported the legislation, pharmaceutical and biotechnology companies claim it will weaken patent protection by reducing infringement penalties and permitting post-approval challenges to patents.

The Senate is also considering similar legislation.

BMS has also been lobbying the Agriculture and Commerce departments and the US Trade Representative's office.

GlaxoSmithKline (GSK) has already instigated a lawsuit which seeks an injunction against the US Patent and Trademark Office (PTO) to stop them from bringing into effect new rules as of 1 November 2007. GSK says the new law will stifle innovation.

30th September 2008

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Dovetail

We’re a specialist health consultancy that supports companies, healthcare professionals and patients to work hand in hand with a common...

Latest intelligence

Robust Review: COVID19 Assessment
See how our client utilized Rapid Payer Response (RPR) to stay informed and gain continuous insights during the recent global pandemic (COVID19)...
Human behaviour - Sept 21
All change – how untangling human behaviour can encourage better health
Driving better patient outcomes through clear, achievable practical steps that are underpinned by transparent evidence...
Health literacy in the time of COVID-19
In a time when much of the media’s focus is on the ongoing COVID-19 pandemic and the differences in vaccination rates between various regions, countries, and socioeconomic groups, improving health...